Net Income

AI hardware innovator Cerebras Systems closes a massive $6.38B IPO, signaling a new front in the battle against NVIDIA with its unique wafer-scale chip.

With U.S. Army contracts and a new Texas factory, EagleNXT is pivoting to defense, adding counter-drone tech and loitering munitions to its arsenal.

A new mixed-income community in Katy leased all 93 units in record time, a stark signal of the urgent, unmet housing demand in a booming Texas region.

An American children's choir finds a second home in Shanghai, using music to build friendships and navigate complex US-China relations.

The 'AI Brain for Batteries' company takes a critical step toward going public, aiming to revolutionize energy storage and electrification via a SPAC deal.

With a new $2 billion credit line, investment fund RoboStrategy is poised to accelerate the AI robotics revolution. But can it balance growth with value?

The Tokyo-based company will issue a US$519K special dividend, a move analysts see as a bid to reward shareholders amid a slumping stock price.

As ARLP heads to a key conference, a tough quarter and a bold diversification strategy put its future in the spotlight for watchful investors.

Facing delisting, Chinese e-mobility firm EZGO enacts a drastic 1-for-150 reverse split. We explore what this means for the company and its investors.

A new report ranks Changi Airport among the world's top carbon emitters, challenging Singapore's sustainable hub ambitions amid rising global pressure.

Glucotrack seeks FDA trial approval for its revolutionary 3-year implantable glucose monitor, racing against financial clocks to change diabetes care.

Amid major Medicare policy shifts, Nuo Therapeutics reports a 169% revenue surge, positioning its Aurix wound care system as a key market disruptor.

Nubank's AI-first strategy drives record revenue and profitability in Mexico, but rising delinquencies test its advanced risk management models.

A Houston firm is set to make waves with a rare Modigliani drawing and a private Dalí painting, complete with personal letters from the artist.

Westaim posted a $33.4M Q1 loss, but strong early sales from its new annuity product suggest a long-term strategic transformation is taking root.

The Solana treasury firm reported a massive GAAP loss due to SOL's price drop, but it also secured new debt, bought back shares, and pushed into new markets.

Out of 600+ plans, Alignment Health is one of just four to earn a top award for medication quality. Here's what that means for seniors and the industry.

Edesa Biotech pushes its pipeline forward with a new vitiligo trial and promising ARDS data, but rising R&D costs highlight the high stakes of innovation.

The chip equipment giant posts record Q2 revenue and profit, driven by surging AI demand, and unveils major partnerships to accelerate future tech.

The biotech firm is set to launch its first commercial products, using an innovative strategy to tackle long-neglected markets in women's healthcare.